Imatinib mesylate: A molecularly targeted therapy for gastrointestinal stromal tumors

ONCOLOGY

Volumn 17, Issue 11, 2003, Pages 1615-1620

  Eisenberg, Burton L ^a,b  

^a FOX CHASE CANCER CENTER   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; DRUG DELIVERY SYSTEM; GASTROINTESTINAL TUMOR; HUMAN; PATHOPHYSIOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; GASTROINTESTINAL NEOPLASMS; HUMANS; NEOADJUVANT THERAPY; PIPERAZINES; PYRIMIDINES;

EID: 2142683026     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Joensuu H, Fletcher C, Dimitrijevic S, et al: Management of malignant gastrointestinal stromal tumours. Lancet Oncol 3:655-664, 2002.
2. Miettinen M, Lasota J: Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 438:1-12, 2001.
3. Mazur MT, Clark HB: Gastric stromal tumors: Reappraisal of histiogenesis. Am J Surg Pathol 7:507-519, 1983.
4. Kindblom LG, Remotti HE, Aldenborg F, et al: Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152:1259-1269, 1998.
5. Erlandson RA, Klimstra DS, Woodruff JM: Subclassification of gastrointestinal stromal tumors based on evaluation by electron microscopy and immunohistochemistry. Ultrastruct Pathol 20:373-393, 1996.
6. Miettinen M, Virolainen M, Maarit- Sarlomo-Rikala: Gastrointestinal stromal tumors-value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol 19:207-216, 1995.
7. Fletcher CD, Berman JJ, Corless C, et al: Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33:459-465, 2002.
8. Hirota S, Isozaki K, Moriyama Y, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580, 1998.
9. Hirota S, Nishida T, Isozaki K, et al: Gain- of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumors. J Pathol 193:505-510, 2001.
10. Nishida T, Hirota S, Taniguchi M, et al: Familial gastrointestinal stromal tumors with germline mutation of the KIT gene. Nat Genet 19:323-324, 1998.
11. Maeyama H, Hidaka E, Ota H, et al: Familial gastrointestinal stromal tumor with hyperpigmentation: Association with a germline mutation of the c-kit gene. Gastroenterology 120:210-215, 2001.
12. Dematteo RP, Lewis JJ, Leung D, et al: Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 231:51-58, 2000.
13. Ng EH, Pollock RE, Munsell MF, et al: Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 215:68-77, 1992.
14. Emory TS, Sobin LH, Lukes L, et al: Prognosis of gastrointestinal smooth muscle (stromal) tumors. Am J Surg Pathol 23:82-87, 1999.
15. Blanke CD, Heinrich MC, Eisenberg BL: Gastrointestinal stromal tumors. Curr Treat Options Oncol 2:485-491, 2001.
16. Edmonson J, Marks R, Buckner J, et al: Contrast of response to D-MAP plus sargramostin between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas (abstract). Proc Am Assoc Cancer Res 18:541a, 1999.
17. Corless C, McGreevey L, Haley A, et al: KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 160:1567-1572, 2002.
18. Pidhorecky I, Cheney RT, Kraybill WG, et al: Gastrointestinal stromal tumors: Current diagnosis, biologic behavior, and management. Ann Surg Oncol 7:705-712, 2000.
19. Eisenberg BL, von Mehren M: Pharmacotherapy of gastrointestinal stromal tumors. Expert Opin Pharmacother 4:869-874, 2003.
20. Tuveson DA, Willis NA, Jacks T, et al: STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: Biological and clinical implications. Oncogene 20:5054-5058, 2001.
21. Rubin B, Singer S, Tsao C, et al: KIT activation is an ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61:8118-8121, 2001.
22. Kitamura Y, Hirota S, Nishida T: Molecular pathology of c-kit proto-oncogene and development of gastrointestinal stromal tumors. Ann Chir Gynaecol 87:282-286, 1998.
23. Miettinen M, Majidi M, Lasota J: Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): A review. Eur J Cancer 38(suppl 5):S39-51, 2002.
24. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibition of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001.
25. Heinrich MC, Griffith DJ, Drucker BJ, et al: Inhibition of c-kit receptor tyrosine kinase by STI 571, a selective tyrosine kinase inhibitor. Blood 96:925-932, 2000.
26. Joensuu H, Dimitrijevic S: Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours. Ann Med 33:451-455, 2001.
27. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al: Effect of the tyrosine kinase inhibitor STI571 in a patient with metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052-1056, 2001.
28. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002.
29. von Mehren M, Blanke C, Joensuu H, et al: High incidence of durable responses induced by imatinib mesylate in patients with unresectable and metastatic gastrointestinal stromal tumor (abstract 1608). Proc Am Soc Clin Oncol 21:403a, 2002.
30. van den Abbeele AD, Badawi RD: Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 38(suppl 5):S60-S65, 2002.
31. van Oosterom AT, Judson I, Verweij J, et al: STI571, an active drug in metastatic gastrointestinal stromal tumors (GIST), an EORTC phase I study (abstract). Proc Am Soc Clin Oncol 20:1a, 2001.
32. Verweij J, van Oosterom A, Blay JY, et al: Imatinib mesylate is an active agent for gastrointestinal stromal tumors but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Eur J Cancer 39:2006-2011, 2003.
33. Benjamin R, Rankin C, Fletcher C, et' al: Phase III dose-randomized study of Imatinib mesylate (IM) for GIST: Intergroup S0033 early results (abstract 3271). Proc Am Soc Clin Oncol 22:814, 2003.
34. Mudan SS, Conlon KC, Woodruff JM, et al: Salvage surgery for patients with recurrent gastrointestinal sarcoma: Prognostic factors to guide patient selection. Cancer 88:66-74, 2000.
35. Heinrich MC, Corless CL, Blanke C, et al: KIT mutational status predicts clinical response to STI571 in patients with metastatic gastrointestinal stromal tumours (GISTs) (abstract 6). Proc Am Soc Clin Oncol 21:2a, 2002.
36. Heinrich MC, Corless CL, von Mehren M, et al: PDGFRA and KIT mutations correlate with the clinical responses to imatinib mesylate in patients with advanced gastrointestinal stromal tumors (GIST) (abstract 3274). Proc Am Soc Clin Oncol 22:815, 2003.
37. Heinrich MC, Corless CL, Duensing A, et al: PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708-710, 2003.
38. Fletcher J, Corless C, Dimitrijevic S, et al: Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST) (abstract 3275). Proc Am Soc Clin Oncol 22:815, 2003.
39. Demetri G, George S, Heinrich MC, et al: Clinical activity and tolerability of the multi- targeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate (abstract 3273). Proc Am Soc Clin Oncol 22:814, 2003.
40. Nielsen TO, West RB, Linn SC, et al: Molecular characterization of soft tissue tumors: A gene expression study. Lancet 359:1301-1307, 2002.
41. Allander SV, Nupponen NN, Ringner M, et al: Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. Cancer Res 61:8624-8628, 2001.
42. Frolov A, Chahwan S, Ochs M, et al: Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors (GISTs). Mol Cancer Ther 9:3653-3654, 2003.
43. Sommer G, Agosti V, Ehlers I, et al: Gastrointestinal stromal tumors in a mouse model by targeted mutation of the KIT receptor tyrosine kinase. Proc Natl Acad Sci 100:6706-6711, 2003.